Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study

This publication has 10 references indexed in Scilit:

• Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy
  Clinical Infectious Diseases, 2006
• Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations
  AIDS, 2006
• SOLO
  AIDS, 2004
• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients
  AIDS, 2004
• The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
• Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
  The Journal of Infectious Diseases, 2004
• Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus
  New England Journal of Medicine, 2003
• Decline in the AIDS and death rates in the EuroSIDA study: an observational study
  The Lancet, 2003
• Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995-1999
  Clinical Infectious Diseases, 2001
• Virologic and Immunologic Consequences of Discontinuing Combination Antiretroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia
  New England Journal of Medicine, 2001